SEHK:9926Biotechs
Akeso (SEHK:9926) Partners With MSK, Is The Discount To Fair Value Justified?
Akeso (SEHK:9926) has drawn fresh investor attention after partnering with Memorial Sloan Kettering Cancer Center on a Phase II study of cadonilimab based therapy for HER2 negative gastric and gastroesophageal junction adenocarcinoma.
See our latest analysis for Akeso.
Akeso's latest collaboration arrives after a mixed stretch in the stock, with the 7 day share price return up 12.62% and the 1 month share price return up 13.71%, but the year to date share price return down 12.18% and the 1...